Group One Trading, L.P. Gain Therapeutics, Inc. Transaction History
Group One Trading, L.P.
- $2.4 Billion
- Q3 2024
A detailed history of Group One Trading, L.P. transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 1,401 shares of GANX stock, worth $2,241. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,401
Previous 7,401
81.07%
Holding current value
$2,241
Previous $9,000
77.78%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding GANX
# of Institutions
23Shares Held
2.39MCall Options Held
10KPut Options Held
0-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$941,4560.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$905,8080.04% of portfolio
-
Joel Greenblatt Gotham Asset Management, LLC | New York, Ny335KShares$535,3470.01% of portfolio
-
Geode Capital Management, LLC Boston, MA272KShares$435,1550.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA145KShares$232,3470.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $19M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...